Respira Therapeutics is developing inhaled therapeutics for cardiopulmonary diseases that improve patient outcomes through enhanced drug targeting to the small airways of the lung. Respira combines proprietary dry-powder inhaler device technologies and advanced particle engineering-based inhaled drug formulation approaches to develop novel therapeutics that deliver the drug where it needs to be —in the lung and lung periphery, instead of in the oropharyngeal cavity. Respira’s lead product candidate, RT234-PAH, has received FDA Orphan Drug Designation for Pulmonary Arterial Hypertension and is in Phase 2 clinical trials as a first-in-class inhaled therapeutic for as-needed use to provide acute relief for the most commonly reported symptoms in PAH patients.
View Top Employees from Respira Therapeutics, Inc.Website | http://www.respiratherapeutics.com |
Revenue | $2 million |
Funding | $2.4 million |
Employees | 14 (10 on RocketReach) |
Founded | 2010 |
Address | Middlefield Rd, Palo Alto, California, US |
Phone | (505) 200-9557 |
Technologies |
HTML,
PHP,
Google Analytics
+6 more
(view full list)
|
Industry | Biotechnology Research, Drug Stores & Pharmacies, Health Care, Retail, Medical, Therapeutics |
Web Rank | 32 Million |
SIC | SIC Code 28 Companies, SIC Code 283 Companies |
NAICS | NAICS Code 325 Companies, NAICS Code 32541 Companies, NAICS Code 32 Companies, NAICS Code 3254 Companies |
Looking for a particular Respira Therapeutics, Inc. employee's phone or email?
The Respira Therapeutics, Inc. annual revenue was $2 million in 2024.
10 people are employed at Respira Therapeutics, Inc..
Respira Therapeutics, Inc. is based in Palo Alto, California.
The NAICS codes for Respira Therapeutics, Inc. are [325, 32541, 32, 3254].
The SIC codes for Respira Therapeutics, Inc. are [28, 283].